Proathlete Wealth Management’s Pfizer PFE Stock Holding History

Proathlete Wealth Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$295K	Sell	12,327 -4,047	-25%	-$106K	0.07%	54
2026 Q1	$460K	Sell	16,374 -928	-5%	-$24.7K	0.13%	44
2025 Q4	$431K	Buy	17,302 +753	+5%	+$19K	0.12%	46
2025 Q3	$422K	Buy	16,549 +206	+1%	+$5.08K	0.12%	46
2025 Q2	$396K	Buy	16,343 +362	+2%	+$8.44K	0.13%	47
2025 Q1	$405K	Buy	15,981 +1,147	+8%	+$30K	0.15%	45
2024 Q4	$394K	Buy	14,834 +171	+1%	+$4.64K	0.15%	47
2024 Q3	$424K	Buy	14,663 +85	+0.6%	+$2.48K	0.17%	46
2024 Q2	$408K	Sell	14,578 -16	-0.1%	-$441	0.19%	46
2024 Q1	$405K	Buy	14,594 +44	+0.3%	+$1.22K	0.22%	44
2023 Q4	$419K	Buy	+14,550	New	+$440K	0.25%	44

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Proathlete Wealth Management's PFE Position: Q2 2026 in Review

Proathlete Wealth Management reduced its Pfizer (PFE) stake by 25% in Q2 2026, selling an estimated $106K and leaving 12,327 shares worth $295K. The position accounts for 0.07% of the portfolio, ranked #54.

Proathlete Wealth Management first reported a position in PFE in Q4 2023 and has held it in 11 quarters since. The position peaked at $460K in Q1 2026. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Proathlete Wealth Management held 12,327 shares of Pfizer worth $295K as of Q2 2026.
Proathlete Wealth Management sold 4,047 Pfizer shares in Q2 2026, an estimated $106K.
Pfizer made up 0.07% of Proathlete Wealth Management's portfolio in Q2 2026, its #54 holding.
Proathlete Wealth Management first reported a position in Pfizer in Q4 2023 and has held it in 11 quarters since.
Proathlete Wealth Management's Pfizer position peaked at $460K in Q1 2026.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Proathlete Wealth Management's 13F filing for Q2 2026, filed 21 Jul 2026.